Not a bad annual report.
Liked the detail on progress and possible options for lani row, shows that they are thinking outside the square.
Did not like the lack of commentary on the two most recent purchases of Maxthera and Prolysis.
OR
chairmans address released, page-2
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)